Korro Bio (NASDAQ:KRRO – Free Report) had its target price cut by Royal Bank of Canada from $105.00 to $95.00 in a research report sent to investors on Wednesday morning,Benzinga reports. They ...

Shares of Korro Bio, Inc. (NASDAQ:KRRO – Get Free Report) have been assigned a consensus rating of “Buy” from the seven ...

Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim ...

RBC Capital lowered the firm’s price target on Korro Bio (KRRO) to $95 from $105 and keeps an Outperform rating on the shares. The firm notes ...

Korro Bio, Inc. (NASDAQ:KRRO), a biotechnology company specializing in RNA editing therapies, has been making significant strides in the development of treatments for rare genetic disorders ...

So, the natural question for Korro Bio (NASDAQ:KRRO) shareholders is whether they should be concerned by its rate of cash burn. In this article, we define cash burn as its annual (negative) free cash ...

March 18, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA ...

Korro Bio completed dosing for its KRRO-110 study in AATD, expects interim results in 2025, and has strong financial resources. Korro Bio, Inc. has completed dosing for the first two cohorts in ...